PAS-004 in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Pasithea Therapeutics Corp. (industry) · KTTA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48estimated
Sites
7
Countries
Bulgaria, Romania, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-29 | actual | When the study began enrolling |
| Primary completion | Feb 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- RAS Mutation
- NF1 Mutation
- RAF Mutation
- Advanced Solid Tumors
Interventions
- Drug: PAS-004 Capsules
- Drug: PAS-004 Tablets
Primary outcomes
what the primary-completion date above is the date OFEvaluation of dose limiting toxicities (DLTs)
measured Day 1 through Day 35 (Cycle 1)
Evaluation of adverse events (AEs)
measured Screening through Day 1 through Day 35 (Cycle 1), and 30 days after discontinuation of study drug
Evaluation of AEs leading to discontinuation of investigational product (IP), PAS-004.
measured Screening through Day 1 through Day 35 (Cycle 1), and 30 days after discontinuation of study drug
Evaluation of hematology laboratory parameters
measured Screening through Day 1 through Day 35 (Cycle 1), and 30 days after discontinuation of study drug
Evaluation of clinical chemistry laboratory parameters
measured Screening through Day 1 through Day 35 (Cycle 1), and 30 days after discontinuation of study drug
Permalink · KTTA's whole pipeline · Catalyst calendar · Every registered study · What changed